SR One and the Oxbridge Biotech Roundtable (OBR) are pleased to announce the 10 finalists for the European stream of the OneStart 2016 programme. These startups are in the top 2 % of this year’s 400 applicants.
“We are delighted that OneStart continues to go from strength to strength. This year’s class of new biotech business are outstanding products of innovation matched with bright and high energy young entrepreneurs, fantastic ingredients with which to build technology companies that can transform the industry and lives of patients”
comments Matt Foy, Partner at SR One.
Since the 40 semi-finalists were chosen back in December 2015 (click here for our press release) each team has made significant progress.
“These startups are our best hopes of tackling some of our most pressing healthcare challenges.”
adds Dan Perez Founder and CEO of OBR/OneStart.
The OneStart programme focuses heavily upon education and mentorship. By supplying these young innovators with the expert guidance they are placed in the best position to develop and move their companies forward. The need for this support is highlighted by
Sarah Haywood, CEO of MedCity.
“Entrepreneurs are the engines of our economy and, in the life sciences sector in particular, they are also energetic drivers of better healthcare and so quality of life for us all. I’ve found it very inspiring to work with OneStart’s young innovators and see their creative new approaches to big human challenges develop into sustainable, growing businesses. I’m proud that MedCity is supporting OneStart to seed exciting new companies and help them succeed.”
The support that OneStart provides can be divided into two-parts 1) Educational Bootcamp and 2) 1-on-1 Mentorship from Industry Experts. The OneStart London Bootcamp was hosted by Queen Mary University of London on 5th and 6th of February this year.
Nooman Haque, the Director of Life Sciences at Silicon Valley Bank describes the Bootcamp.
“The Bootcamp is an intensive experience for the entrepreneurs that provides direct feedback and engagement from a wide range of industry experts, including law, finance and Pharma. Within two days this programme equips participants with advice that would typically take years of industry experience to collect.”
Niall McAlister, Partner at Olswang LLP adds,
"This 2-day 'mini-MBA' is a fantastic opportunity for the OneStart entrepreneurs to learn from some of the biggest names in the sector about how to turn their great ideas into investable business propositions, as well as how to start to build the networks they will need to support them as they move forward."
Each semi-finalist team was also given the opportunity to practice their pitch, a vital skill for any up and coming entrepreneur. Dr. Aric Orbach, Head of Pharmacology at Teva Pharmaceutical Industries tells us more.
"The Bootcamp really brought these amazing projects to life and gave us an opportunity to see the progress that has been made by the teams. The whole process was compelling and inspiring – we have some wonderful young talent out there working on projects that can really change the face of healthcare."
Post-Bootcamp all semi-finalists worked closely with several industry mentors over a 5-6 week period. These experts provided 1-on-1 feedback and advice on their 5-page business plans and 10-slide pitch decks, the two documents required to be submitted by every OneStart semi-finalist team.
"It is great fun mentoring a team, seeing the starting idea - which has to be valid and exciting in order to make it through the initial steps, evolve to a solid business case. The enthusiasm is what separates good teams from great teams. Also, I’ve enjoyed seeing the hope that their idea has weight but then also being flexible to feedback and receptive to objective input on what any future investor might be looking for. The competition is definitely a journey for everyone,"
comments Dr. Lynne Murray, Partnering and Strategy at MedImmune (worldwide biologics division of AstraZeneca).
The OneStart experience also provides individuals with the skill sets required to be successful entrepreneurs, as illustrated by Dr. Claire Brown, an Investment Manager at Alderley Park Ventures and BioCity.
"Once again I was delighted to see the quality of companies entering the programme. Like many investors, I am always on the look out for an investable team.. but what makes a team investable? Many things but two attributes I look for 1) complimentary expertise 2) a willingness to learn what they don’t yet know. Teams who have fully embraced the mentorship offered by OneStart, soaking up key information at every turn, will, in my experience, ultimately lead more successful companies whether their current technology is the one they ultimately progress to fruition…"
Each business plan and pitch deck was thoroughly assessed by the OneStart judges. The top-10 ranked teams (click here for the Europe finalists) were chosen to progress to the last stage of the programme.
The 10 finalists will now work to expand both of these assets to create an in depth 10-page business plan and 20-slide pitch deck. The programme culminates with our Finals Gala in London on 16th May. A day of pitching will be followed by a 3-course meal to celebrate not only the finalists but also bio-entrepreneurship.
The winner, announced at the end of the Gala (May 16th) will be presented with a cheque for £100,000 (non-dilutive) and guaranteed, free lab space. However, the main prize is the continued guidance and support supplied from the OneStart network far beyond the 2016 programme. Importantly this is naturally extended to all semi-finalist teams.
Lastly, we would like to extend our sincere gratitude and thanks to our OneStart Global: Takeda Ventures Inc., Bristol-Myers Squibb, GSK, Roche, AstraZeneca, MedImmune, Boehringer Ingelheim, Teva Pharmaceutical Industries, McKinsey & Company, Silicon Valley Bank and European 2016 partners - Johnson and Johnson Innovation, Olswang, MedCity and BioCity. They are integral to the continued success and growth of the programme. This sentiment is echoed by OneStart co-founder Dan Perez.
“We wouldn’t be able to support our start-ups without our incredible industry partners who have selflessly guided our teams through critical stages in their development.”
Cambridge Bio-Augmentation Systems Ltd. - Cambridge, United Kingdom
The USB port for prostheses: a low-cost, standardised connector enabling mass adoption of high functionality bionics.
Captain T Cell - Berlin, Germany.
Providing next generation T cell receptors for cancer immunotherapy.
DJS Antibodies - Oxford, United Kingdom.
DJS Antibodies is using a breakthrough technology to discover new medicines against currently untreatable diseases.
Eonia Therapeutics - Cambridge, United Kingdom.
Small molecules that promote T-cell memory formation.
gripAble - London, United Kingdom.
gripAble: A low-cost, highly-motivating technology providing mobile rehabilitation for individuals with arm disability.
ITAM Pharma - Padova, Italy.
Merging the gold anticancer properties with the targeting & chemoprotecting action of ad hoc functionalized biomolecules.
LabGenius - London, United Kingdom.
LabGenius’ platform for optimising antibody discovery enables pharma companies to develop better therapies faster.
Reproomics - Oxford, United Kingdom.
Reproomics improves the outcome of assisted reproduction treatments by measuring protein biomarkers of embryo competence.
S-Biomedic - Magdeburg, Germany.
Our live biotherapeutics are the future in dermatology and cosmetic industry.
snap40 - Edinburgh, United Kingdom.
snap40 aim to prevent avoidable acute patient health deteriorations, in hospital and in the community.
For more details about OneStart 2016, see www.onestart.co.
Notes for Editors
Interviews available with the CEO on request – please contact Jessica Sutcliffe on firstname.lastname@example.org.
About Oxbridge Biotech Roundtable (OBR) www.oxbridgebiotech.com
Oxbridge Biotech Roundtable was founded in 2011 with the aim of creating better ties between academia and industry. This is achieved through encouraging enhanced communication and consultancy between the two sectors, with a 30,000 strong network of academic and industrial professionals.
About SR One™ www.srone.com
SR One is the independent corporate healthcare venture capital fund of GlaxoSmithKline (GSK). Founded in 1985 they have invested over $830MM into the biotechnology sector, with a 35 strong public and private portfolio, investing globally in companies that will have a significant impact on medical care.
About OneStart www.onestart.co
OneStart is the world’s largest life sciences and healthcare startup accelerator programme. Founded in 2012 it aims to encourage entrepreneurship among young and disruptive healthcare innovators. Applications are open to all, from early to more developed businesses, whose idea focuses on improving human healthcare, irrespective of the type of technology. Participation is limited to individuals under the age of 36 and companies who have not raised more than £160,000 / $250,000 in dilutive funding.